Zerigo Health
Zerigo Health is a San Diego-based private medical device company that markets the first FDA-cleared portable narrowband UVB phototherapy system, paired with a machine-learning mobile app and Care Guide support, for at-home treatment of psoriasis, eczema, and vitiligo, sold primarily to U.S. health plans, self-insured employers, and individual patients via prescription.
- Company typePrivate
- Founded2017
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Zerigo Health does
Zerigo Health is a San Diego-based, venture-backed private medical device and digital health company that develops and markets the first FDA-cleared portable narrowband UVB (NB-UVB) phototherapy system for at-home treatment of chronic skin conditions, including psoriasis, eczema, vitiligo, seborrheic dermatitis, and leukoderma across all Fitzpatrick skin types (I-VI). The platform pairs the handheld phototherapy device via Bluetooth to a companion iOS and Android mobile app that uses machine-learning to personalize dosing according to American Academy of Dermatology (AAD2) protocols, with cloud-based prescription control enforcing physician-prescribed regimens, photo-based progress tracking, and remote monitoring by dedicated Care Guides. The company also offers Virtual Visits for remote diagnosis and prescription.
The business operates a B2B2C model in which health plans and self-insured employers contract for the Zerigo Skin Health Program as a covered benefit with a 30-day implementation timeline, supplemented by direct-to-consumer acquisition through physician prescriptions and the company's own website enrollment flow. Channel partners include benefits consultants, PBMs, and distribution networks, with a 2022 strategic partnership with Artemis Health embedding Zerigo into payer and employer benefits-analytics workflows. Revenue is generated through device provision covered by employer health plans, insurance reimbursement under Medicare DMEPOS supplier standards, and multi-year contracts with risk-bearing buyers targeting the specialty-drug cost category for chronic skin conditions.
The company was founded in 2014 (FDA clearance of the device followed in May 2017), has raised approximately $67 million in cumulative outside capital across seed, Series A, and a $43 million Series B in October 2021, and operates with 11-50 employees from its headquarters in San Diego, California, serving U.S. patients only. Recent strategic activity through 2022-2024 has centered on expanding clinical indications (eczema), launching the Zerigo 2.0 platform, building payer-facing analytics partnerships, and refreshing the executive bench with CEO Lisa Rometty and a CGO/CPO/CMO/CFO suite drawn from CVS Health, Optum Rx, UnitedHealthcare, Express Scripts, and Amazon Health Services.
Zerigo Health firmographics
Firmographics- Name
- Zerigo Health
- Legal name
- Zerigo Health, Inc.
- Website
- https://zerigohealth.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Zerigo Health is a San Diego-based private medical device company that markets the first FDA-cleared portable narrowband UVB phototherapy system, paired with a machine-learning mobile app and Care Guide support, for at-home treatment of psoriasis, eczema, and vitiligo, sold primarily to U.S. health plans, self-insured employers, and individual patients via prescription.
- Ownership category
- akta.pro rank
Zerigo Health industry classification
Industry- Product category
- Connected home phototherapy for chronic skin conditions
- NAICS
- Hair, Nail, and Skin Care Services (81211)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Psoriasis & Eczema Specialty Care (HLAKACAL)
- akta.pro secondary industries
- Pigmentary Disorders (Vitiligo/Melasma) (HLAKACAM), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)
Keywords
Where Zerigo Health is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Zerigo Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Device Sales / Insurance Reimbursement: Zerigo Health offers its FDA-cleared phototherapy device which may be covered through employer health plans at no cost to members, or reimbursed through insurance depending on diagnosis, medical history, and individual coverage policies. The device requires a physician prescription.
- B2B Health Plan and Employer Contracts: Zerigo Health generates revenue through partnerships with health plans and self-insured employers who offer the Zerigo Solution as a benefit to their members/employees, targeting reduction in specialty drug costs for chronic skin conditions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Employer/Health Plan Sponsored Benefit |
| Other | Pay-as-you-go | Insurance Reimbursement |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Zerigo Health product offering
Product offeringCore offering
Zerigo Health sells the Zerigo Skin Health Program, an FDA-cleared at-home connected phototherapy system combining a handheld narrowband UVB device, a Bluetooth-paired mobile app that uses machine-learning to personalize dosing and track progress, and dedicated Care Guide support plus Virtual Visits with licensed prescribers. The program treats chronic skin conditions including psoriasis, eczema/atopic dermatitis, vitiligo, seborrheic dermatitis, and leukoderma on all Fitzpatrick skin types I–VI, and is delivered to members through health plan and self-insured employer benefit contracts or direct physician prescription.
Product overview
Zerigo Health offers the Zerigo Skin Health Program, a unified digital health platform that combines three core components: (1) the Zerigo Phototherapy Device — an FDA-cleared handheld NB-UVB phototherapy device that patients use at home or on the go, (2) the Zerigo Mobile App — which connects to the device via Bluetooth, uses machine-learning to personalize treatment dosing, and enables progress tracking through photo uploads, and (3) Zerigo Care Guides — dedicated support staff who provide coaching and technical assistance throughout the treatment journey. The platform also integrates Virtual Visits with licensed providers for remote diagnosis and prescription. Treatment protocols follow American Academy of Dermatology guidelines, with dosing controlled automatically by the device based on the patient's prescribed Fitzpatrick skin type. The system targets patients with psoriasis, atopic dermatitis (eczema), vitiligo, seborrheic dermatitis, and leukoderma across all skin types (I–VI).
Differentiator
Problem solved
Functional benefit
Products and services
- Zerigo Skin Health Program Comprehensive at-home phototherapy program combining the FDA-cleared handheld NB-UVB device, the Zerigo Mobile App with machine-learning personalization, dedicated Care Guide support, and Virtual Visits with licensed providers, designed for individuals with chronic skin conditions including psoriasis, eczema, vitiligo, seborrheic dermatitis, and leukoderma.
- Zerigo Phototherapy Device The first FDA-cleared portable narrowband UVB phototherapy handheld device that delivers clinical-grade light therapy in the user's home or on the go and pairs with the Zerigo Mobile App via Bluetooth to enforce physician-prescribed dosing protocols.
- Zerigo Mobile App Companion iOS and Android application that pairs with the Zerigo Phototherapy Device via Bluetooth, uses machine-learning to personalize treatment plans, tracks progress through photo uploads, sends treatment reminders, and connects patients to their Care Guides and prescribing physicians.
- Zerigo Care Guides Dedicated support team of RNs, MAs, and certified health and wellness coaches who onboard patients, drive treatment adherence, provide technical support, and coordinate with prescribing physicians throughout the treatment journey.
- Virtual Visits Access to licensed healthcare providers who can remotely diagnose chronic skin conditions and prescribe the Zerigo device, enabling patients to begin treatment without requiring in-person clinic visits.
- Zerigo 2.0 Ecosystem Updated version of the Zerigo platform with integrated guideline-recommended NB-UVB phototherapy dosing protocols that shorten in-home treatment time for psoriasis and eczema patients by half compared with prior protocols.
- Zerigo Eczema Solution Indication-specific extension of the Zerigo platform with integrated, guideline-recommended phototherapy dosing protocols for atopic dermatitis (eczema), complementing the existing psoriasis and vitiligo treatments.
Quantifiable outcome
- 73% treatment adherence rate among engaged Zerigo members
- +4 more outcomes
Companies that use Zerigo Health
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Zerigo Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Zerigo Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Artemis HealthcorePartnership to help employers and health plans evaluate and manage rising specialty drug costs for chronic autoimmune skin conditions. Artemis clients gain access to Console analytics to measure Zerigo's impact on outcomes, quality of life, and costs. Clients can add Zerigo to benefits through existing Artemis agreements.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Zerigo Health competitors and assessment
Company assessmentDirect peers
- Daavlin: Manufacturer of phototherapy equipment (full-body and targeted NB-UVB/UVA systems) for dermatology clinics and home use. Most directly comparable to Zerigo as a NB-UVB phototherapy device maker; differences are channel (clinic/office-led vs. Zerigo's at-home, connected model) and integration with software/ML dosing.
- National Biological Corporation: Long-established US manufacturer of phototherapy cabinets and home phototherapy units for psoriasis and vitiligo. Competes in the same NB-UVB modality, though primarily through clinic-channel and capital equipment sales rather than Zerigo's connected, app-driven at-home model.
- Sensus Healthcare: Public dermatology device company offering superficial radiation therapy (SRT) and aesthetic laser systems used by dermatologists. A direct device-vendor peer in the dermatology treatment-device category, with overlap on regulatory pathway (FDA-cleared) and clinical buyer (dermatology practices).
Broad incumbents
- Hims & Hers Health: Large direct-to-consumer telehealth platform offering prescription treatments for skin, hair, sexual health, and mental health. Comparable as a DTC, employer-/payer-aware digital health brand in dermatology, but competes more with topical/oral therapies than with at-home phototherapy specifically.
- Ro: Direct-to-consumer telehealth company operating the Roman dermatology vertical with prescription topical and oral treatments for skin conditions. Overlaps with Zerigo on the dermatology DTC/online prescribing funnel and on the chronic skin condition patient, but is treatment-modality-adjacent rather than a device peer.
- Livongo (Teladoc Health): Chronic-condition digital health platform founded by Glen Tullman, now part of Teladoc Health. Closely comparable business model (connected device + coaching + data, B2B payer contracting) and serves as the strategic reference point for Zerigo's executive playbook, even though dermatology was not Livongo's focus.
- AbbVie (Skyrizi): Pharmaceutical incumbent whose Skyrizi (risankizumab) is a leading IL-23 biologic for psoriasis and a direct therapeutic alternative to NB-UVB phototherapy. Represents the largest competitive threat to Zerigo on the payer formulary side, given Skyrizi's share of dermatology specialty drug spend.
- Novartis (Cosentyx): Pharmaceutical incumbent marketing Cosentyx (secukinumab), a leading IL-17 biologic for psoriasis, psoriatic arthritis, and related conditions. Competes with Zerigo for the same patients and payer dollars, but via systemic drug therapy rather than at-home phototherapy.
Emerging players
- Omada Health: Digital chronic-condition management company selling to health plans and employers (diabetes, hypertension, prediabetes). Highly comparable GTM motion (B2B health plan and employer sales, outcomes-based contracts) and connected device/coaching service model, though its conditions of focus differ from Zerigo's dermatology scope.
- Photocil (IncellDx): Emerging home phototherapy solution for vitiligo, positioned as a direct-to-consumer device with app integration. Closest emerging competitor in the connected, at-home NB-UVB category, especially in the vitiligo indication where Zerigo is also cleared.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Zerigo Health social profiles
Digital presenceZerigo Health compliance and trust
Trust signalCompliance4 records
Zerigo Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zerigo Health leadership team
Management profileNumber of profiles
Profiles11 records
Zerigo Health funding detail
Funding detailFunding overview
Funding rounds9 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zerigo Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zerigo Health
What does Zerigo Health do?
Zerigo Health sells the Zerigo Skin Health Program, an FDA-cleared at-home connected phototherapy system combining a handheld narrowband UVB device, a Bluetooth-paired mobile app that uses machine-learning to personalize dosing and track progress, and dedicated Care Guide support plus Virtual Visits with licensed prescribers. The program treats chronic skin conditions including psoriasis, eczema/atopic dermatitis, vitiligo, seborrheic dermatitis, and leukoderma on all Fitzpatrick skin types I–VI, and is delivered to members through health plan and self-insured employer benefit contracts or direct physician prescription.
Is Zerigo Health a public or private company?
Zerigo Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Zerigo Health founded?
Zerigo Health was founded in 2017. It employs 11 to 50 people.
Where is Zerigo Health based?
Zerigo Health is headquartered in La Jolla, United States, in the North America region.
How does Zerigo Health make money?
Two revenue lines are on record. Device Sales / Insurance Reimbursement is the primary driver. The others are B2B Health Plan and Employer Contracts.
Who are Zerigo Health's main competitors?
Direct peers on record are Daavlin, National Biological Corporation and Sensus Healthcare. Broad incumbents are Hims & Hers Health, Ro, Livongo (Teladoc Health), AbbVie (Skyrizi) and Novartis (Cosentyx). Emerging players are Omada Health and Photocil (IncellDx).
Does Zerigo Health have an API?
No public API is recorded for Zerigo Health.
What industry is Zerigo Health in?
Zerigo Health's product category is Connected home phototherapy for chronic skin conditions. Its primary akta.pro industry code is HLAKACAL, Psoriasis & Eczema Specialty Care, with a secondary code of HLAKACAM, Pigmentary Disorders (Vitiligo/Melasma). Its NAICS code is 81211 and its SIC code is 8000.